Among the treatments that could be considered for future treatment is the usage of metreleptin, a recombinant analog of human leptin, which has been approved for the treatment of generalized lipodystrophy, a rare metabolic disorder characterized by the loss of adipose tissue [20,23,39]. The gene discussed is LEP; the disease is generalized lipodystrophy.